Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16081-

  Dashkoff, Jonathan ^a,b   Lerner, Eli P ^b   Truong, Nhi ^b   Klickstein, Jacob A ^b   Fan, Zhanyun ^b   Mu, Dakai ^c   Maguire, Casey A ^c   Hyman, Bradley T ^b   Hudry, Eloise ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; ADENO ASSOCIATED VIRUS VECTOR 9; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEIN; SYNAPSIN; UNCLASSIFIED DRUG; CALBINDIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CELL MARKER; CHOLINE ACETYLTRANSFERASE; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DECARBOXYLASE 67; IBA 1 PROTEIN; MEMBRANE PROTEIN; NEURON SPECIFIC NUCLEAR PROTEIN; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; CENTRAL NERVOUS TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE EXPRESSION; MOTONEURON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SPINAL CORD; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL CELL; BLOOD BRAIN BARRIER; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM; GENETIC TRANSDUCTION; HUMAN; MALE; NERVE CELL; PURKINJE CELL; SPINAL CORD MOTONEURON; TRANSGENE EXPRESSION;

EID: 85015192968     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.81     Document Type: Article

References (50)

1. 1 Craig, AJ, Housley, GD, Evaluation of gene therapy as an intervention strategy to treat brain injury from stroke. Front Mol Neurosci, 9, 2016, 34.
2. 2 Gessler, DJ, Gao, G, Gene therapy for the treatment of neurological disorders: metabolic disorders. Methods Mol Biol 1382 (2016), 429–465.
3. 3 Bourdenx, M, Dutheil, N, Bezard, E, Dehay, B, Systemic gene delivery to the central nervous system using adeno-associated virus. Front Mol Neurosci, 7, 2014, 50.
4. 4 Gelfand, Y, Kaplitt, MG, Gene therapy for psychiatric disorders. World Neurosurg 80 (2013), S32.e11–S32.e18.
5. 5 Bennett, J, Ashtari, M, Wellman, J, Marshall, KA, Cyckowski, LL, Chung, DC, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med, 4, 2012, 120ra15.
6. 6 Maguire, AM, High, KA, Auricchio, A, Wright, JF, Pierce, EA, Testa, F, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374 (2009), 1597–1605.
7. 7 Worgall, S, Sondhi, D, Hackett, NR, Kosofsky, B, Kekatpure, MV, Neyzi, N, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 19 (2008), 463–474.
8. 8 Janson, C, McPhee, S, Bilaniuk, L, Haselgrove, J, Testaiuti, M, Freese, A, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 13 (2002), 1391–1412.
9. 9 Guo, Y, Wang, D, Qiao, T, Yang, C, Su, Q, Gao, G, et al. A single injection of recombinant adeno-associated virus into the lumbar cistern delivers transgene expression throughout the whole spinal cord. Mol Neurobiol 53 (2016), 3235–3248.
10. 10 Hironaka, K, Yamazaki, Y, Hirai, Y, Yamamoto, M, Miyake, N, Miyake, K, et al. Enzyme replacement in the CSF to treat metachromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary AAV1 vector. Sci Rep, 5, 2015, 13104.
11. 11 Hordeaux, J, Dubreil, L, Deniaud, J, Iacobelli, F, Moreau, S, Ledevin, M, et al. Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats. Gene Ther 22 (2015), 316–324.
12. 12 Hinderer, C, Bell, P, Gurda, BL, Wang, Q, Louboutin, JP, Zhu, Y, et al. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol Ther 22 (2014), 2018–2027.
13. 13 Haurigot, V, Marcó, S, Ribera, A, Garcia, M, Ruzo, A, Villacampa, P, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 123:8 (2013), 3254–3271.
14. 14 Hudry, E, Dashkoff, J, Roe, AD, Takeda, S, Koffie, RM, Hashimoto, T, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med, 5, 2013, 212ra161.
15. 15 Levites, Y, Jansen, K, Smithson, LA, Dakin, R, Holloway, VM, Das, P, et al. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 26 (2006), 11923–11928.
16. 16 Beutler, AS, Banck, MS, Walsh, CE, Milligan, ED, Intrathecal gene transfer by adeno-associated virus for pain. Curr Opin Mol Ther 7 (2005), 431–439.
17. 17 Murrey, DA, Naughton, BJ, Duncan, FJ, Meadows, AS, Ware, TA, Campbell, KJ, et al. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev 25 (2014), 72–84.
18. 18 Mattar, CN, Waddington, SN, Biswas, A, Johana, N, Ng, XW, Fisk, AS, et al. Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Ther 20 (2013), 69–83.
19. 19 Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM, Kaspar, BK, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27 (2009), 59–65.
20. 20 Pleger, ST, Shan, C, Ksienzyk, J, Bekeredjian, R, Boekstegers, P, Hinkel, R, et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med, 3, 2011, 92ra64.
21. 21 Hudry, E, Martin, C, Gandhi, S, György, B, Scheffer, DI, Mu, D, et al. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther 23 (2016), 380–392.
22. 22 Deverman, BE, Pravdo, PL, Simpson, BP, Kumar, SR, Chan, KY, Banerjee, A, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 34 (2016), 204–209.
23. 23 Gray, SJ, Matagne, V, Bachaboina, L, Yadav, S, Ojeda, SR, Samulski, RJ, Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19 (2011), 1058–1069.
24. 24 McCarty, DM, Self-complementary AAV vectors; advances and applications. Mol Ther 16 (2008), 1648–1656.
25. 25 Iwata, N, Sekiguchi, M, Hattori, Y, Takahashi, A, Asai, M, Ji, B, et al. Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep, 3, 2013, 1472.
26. 26 Fu, H, Dirosario, J, Killedar, S, Zaraspe, K, McCarty, DM, Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 19 (2011), 1025–1033.
27. 27 Benkhelifa-Ziyyat, S, Besse, A, Roda, M, Duque, S, Astord, S, Carcenac, R, et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther 21 (2013), 282–290.
28. 28 Yamashita, T, Chai, HL, Teramoto, S, Tsuji, S, Shimazaki, K, Muramatsu, S, et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol Med 5 (2013), 1710–1719.
29. 29 Sarukhan, A, Camugli, S, Gjata, B, von Boehmer, H, Danos, O, Jooss, K, Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 75 (2001), 269–277.
30. 30 Brockstedt, DG, Podsakoff, GM, Fong, L, Kurtzman, G, Mueller-Ruchholtz, W, Engleman, EG, Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 92 (1999), 67–75.
31. 31 Zincarelli, C, Soltys, S, Rengo, G, Rabinowitz, JE, Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16 (2008), 1073–1080.
32. 32 Huda, F, Konno, A, Matsuzaki, Y, Goenawan, H, Miyake, K, Shimada, T, et al. Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model. Mol Ther Methods Clin Dev, 1, 2014, 14032.
33. 33 Lawlor, PA, Bland, RJ, Mouravlev, A, Young, D, During, MJ, Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17 (2009), 1692–1702.
34. 34 Kügler, S, Kilic, E, Bähr, M, Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther 10 (2003), 337–347.
35. 35 Lee, Y, Messing, A, Su, M, Brenner, M, GFAP promoter elements required for region-specific and astrocyte-specific expression. Glia 56 (2008), 481–493.
36. 36 Wu, J, Zhao, W, Zhong, L, Han, Z, Li, B, Ma, W, et al. Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther 18 (2007), 171–182.
37. 37 Maguire, CA, Crommentuijn, MH, Mu, D, Hudry, E, Serrano-Pozo, A, Hyman, BT, et al. Mouse gender influences brain transduction by intravascularly administered AAV9. Mol Ther 21 (2013), 1470–1471.
38. 38 Anlauf, E, Derouiche, A, Glutamine synthetase as an astrocytic marker: its cell type and vesicle localization. Front Endocrinol (Lausanne), 4, 2013, 144.
39. 39 Kraft, AW, Hu, X, Yoon, H, Yan, P, Xiao, Q, Wang, Y, et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J 27 (2013), 187–198.
40. 40 Wang, Z, Ma, HI, Li, J, Sun, L, Zhang, J, Xiao, X, Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 10 (2003), 2105–2111.
41. 41 McCarty, DM, Monahan, PE, Samulski, RJ, Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8 (2001), 1248–1254.
42. 42 Bosch, MK, Nerbonne, JM, Ornitz, DM, Dual transgene expression in murine cerebellar Purkinje neurons by viral transduction in vivo. PLoS One, 9, 2014, e104062.
43. 43 Mingozzi, F, High, KA, Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122 (2013), 23–36.
44. 44 Zaiss, AK, Muruve, DA, Immune responses to adeno-associated virus vectors. Curr Gene Ther 5 (2005), 323–331.
45. 45 Verkhratsky, A, Parpura, V, Pekna, M, Pekny, M, Sofroniew, M, Glia in the pathogenesis of neurodegenerative diseases. Biochem Soc Trans 42 (2014), 1291–1301.
46. 46 Maragakis, NJ, Rothstein, JD, Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2 (2006), 679–689.
47. 47 Xiong, W, Cepko, C, Distinct expression patterns of AAV8 vectors with broadly active promoters from subretinal injections of neonatal mouse eyes at two different ages. Adv Exp Med Biol 854 (2016), 501–507.
48. 48 Choudhury, SR, Harris, AF, Cabral, DJ, Keeler, AM, Sapp, E, Ferreira, JS, et al. Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector. Mol Ther 24 (2016), 726–735.
49. 49 Yang, B, Li, S, Wang, H, Guo, Y, Gessler, DJ, Cao, C, et al. Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther 22 (2014), 1299–1309.
50. 50 Borchelt, DR, Ratovitski, T, van Lare, J, Lee, MK, Gonzales, V, Jenkins, NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19 (1997), 939–945.